Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma, B-Cell × Alemtuzumab × Clear all

Phase

Status

Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 2 Lymphoma, B-Cell 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 22 fludarabine 15 Rituximab 13 Immunotherapy, Adoptive 9 Vincristine 7 Specimen Handling 7 Prednisone 7 Magnetic Resonance Spectroscopy 7 Etoposide 7 Doxorubicin 7 glofitamab 6 Biopsy 6 zanubrutinib 4 polatuzumab vedotin 4 obinutuzumab 4 Lenalidomide 4 Ifosfamide 4 Dexamethasone 4 Carboplatin 4 Bendamustine Hydrochloride 4 tafasitamab 3 relmacabtagene autoleucel 3 loncastuximab tesirine 3 fludarabine phosphate 3 etoposide phosphate 3 axicabtagene ciloleucel 3 Leukapheresis 3 Gemcitabine 3 X-Rays 2 Nivolumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05607420 2025-08-24

NatHaLi-01

Cellectis S.A.

Phase 1/2 Recruiting

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡